一分钟看懂
这是一项关于乳腺癌的III 期研究，登记的药物或干预包括AZD9833；Anastrozole；Anastrozole placebo；AZD9833 placebo；Palbociclib；Luteinizing hormone-releasing hormone (LHRH) agonist，当前状态为研究进行中，已停止招募。登记地点显示中国保定、北京、蚌埠、长春等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
AZD9833；Anastrozole；Anastrozole placebo；AZD9833 placebo；Palbociclib；Luteinizing hormone-releasing hormone (LHRH) agonist · III 期
登记条件中文摘要
年龄范围：18岁至130岁
登记的基本范围为不限性别，年龄18岁至130岁；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Research Site · 保定
- Research Site · 北京
- Research Site · 蚌埠
- Research Site · 长春
- Research Site · 长沙
- Research Site · 成都
- Research Site · 重庆
- Research Site · 大连
- Research Site · 广州
- Research Site · 贵阳
- Research Site · 海口
- Research Site · 杭州
- Research Site · 合肥
- Research Site · 济南
- Research Site · 兰州
- Research Site · 临沂
- Research Site · 南昌
- Research Site · 南京
- Research Site · 上海
- Research Site · 沈阳
- Research Site · 天津
- Research Site · 武汉
- Research Site · 西安
- Research Site · 郑州
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- Full list of inclusion criteria
- * Pre-/peri-menopausal women or men can be enrolled if amenable to be treated with concomitant, approved LHRH agonists for the duration of the study treatment.
- * De novo Stage 4 disease, or recurrence from early stage disease after at least 24 months of standard adjuvant endocrine therapy. Note that at least 12 months must have elapsed since the patient's last dose of adjuvant AI therapy without disease progression on treatment. Note that a 2-week washout period is required after the last dose of tamoxifen prior to randomisation.
- * Histologically or cytologically documented diagnosis of ER+, HER2-negative breast cancer based on local laboratory results.
- * Previously untreated with any systemic anti-cancer therapy for their locoregionally recurrent or metastatic ER+ disease.
- * Measurable disease as defined per RECIST v.1.1 OR at least one lytic or mixed (lytic + sclerotic) bone lesion with a soft tissue component that can be assessed by CT or MRI.
- * Eastern Cooperative Oncology Group performance status of 0 or 1.
- * Adequate organ and marrow function.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT04711252；登记信息更新于 2026-09-28；本站同步于 2026-10-08。